Reliability of core needle biopsy for HER2-low early-stage breast cancer
These findings suggest that HER2 status should be retested, particularly for large tumors initially diagnosed as HER2-0, in light of new effective therapies for HER2-low breast cancer, such as antibody-drug conjugates.
Authors
- S. Di Cosimo
- Maria Carmen De Santis (ORCID: https://orcid.org/0000-0003-3131-3969)
- Chiara Maura Ciniselli (ORCID: https://orcid.org/0000-0003-4488-885X)
- Filippo de Braud (ORCID: https://orcid.org/0000-0003-0103-730X)
- Paolo Verderio (ORCID: https://orcid.org/0000-0002-9231-1281)
- C. Depretto
- Cinzia De Marco (ORCID: https://orcid.org/0000-0003-1153-270X)
- V. Duroni
- Paolo Baili (ORCID: https://orcid.org/0000-0003-0335-2418)
- S. Pizzamiglio
- Maria Grazia Carnevale (ORCID: https://orcid.org/0000-0003-3251-0139)
- S. Folli
- A. Vingiani
- G. Pruneri
- G. Scaperrotta
Institutions
- University of Milan (IT)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
Publication Details
- Journal
- Clinical & Translational Oncology
- Published
- 2025-03-09
- DOI
- https://doi.org/10.1007/s12094-025-03877-2
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- European Commission
- Associazione Italiana per la Ricerca sul Cancro